ArticleJournal of thoracic disease2025
The efficacy of azvudine in treating hospitalized COVID-19 patients: a retrospective single-center cohort analysis.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although coronavirus disease 2019 (COVID-19) is no longer classified as a Public Health Emergency of International Concern (PHEIC), the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to undergo genetic mutations, leading to persistent public health challenges. It is still necessary to evaluate the effectiveness and safety of existing clinical drug treatments. In this study, we mainly evaluate the treatment effect of azvudine in the real world of hospitalized COVID-19 patients. Methods: This retrospective cohort analysis included hospitalized patients diagnosed with COVID-19 from December 1, 2022, to October 31, 2023. Patients receiving azvudine were categorized as the treatment group, while those without antiviral therapy constituted the control group. The primary endpoint was the rate of composite outcome of disease progression within a 38-day observation period. Secondary endpoints included all-cause mortality, incidence of intensive care unit (ICU) admission, and the rate of receiving ventilator-assisted ventilation. Results: Of 939 hospitalized COVID-19 patients, 260 were included in the final analysis after exclusions and propensity score matching (1:1), with 130 in each group. In the azvudine group, only one patient required invasive ventilation, was admitted to ICU, and ultimately passed away. In the matched control group, the rate of the composite outcome of disease progression was 9.23% (12/130), the all-cause mortality was 5.38% (7/130), the incidence of ICU admission was 5.38% (7/130), and the incidence of receiving ventilator-assisted ventilation was 6.15% (8/130). The treatment of azvudine showed a significant reduction in the endpoints, including the rate of the composite outcome of disease progression (P=0.02) and receiving ventilator-assisted ventilation (P=0.047). Azvudine was linked to a lower combined risk of disease progression [hazard ratio (HR): 0.08, 95% confidence interval (CI): 0.01 to 0.62] and ventilator-assisted ventilation needs (HR: 0.12, 95% CI: 0.02 to 0.97). It reduced the risk of composite outcome of disease progression [absolute risk reduction (ARR): 0.08, 95% CI: 0.02 to 0.15; number needed to treat (NNT): 12, 95% CI: 7 to 50]. Conclusions: The findings show that azvudine is effective in treating hospitalized COVID-19 patients. It could be considered for therapeutic use in this patient population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.